Alterations in the coagulation markers did not show differences with the severity of COVID‐19 in Peruvian patients: A cross‐sectional single‐center study

BACKGROUND AND AIMS: COVID‐19 is a pandemic disease that can lead to altered lung function, systemic inflammatory events, and altered coagulation. During severe stages of the disease, changes in coagulation homeostasis increase, leading to thrombosis, and increased risk of death. In this cross‐sectional study, we aimed to assess coagulation markers by COVID‐19 severity in Peruvian adults. METHODS: During the second wave of infections, we included 186 adults diagnosed with COVID‐19 (mean age 53.3 ± 16.3 years). Patients were divided into mild, moderate, and severe stages of COVID‐19, and coagulation markers included prothrombin time (PT), activated partial prothrombin time (aPTT), fibrinogen, d‐dimer, and platelet count. RESULTS: Of the total, 120 (64.5%) were males and 39 (21%) were in the intensive care unit. We determine 104 (55.9%), 43 (24.7%), and 36 (19.4%) patients in mild, moderate, and severe stages of COVID‐19, respectively. In the severe stage of COVID‐19, patients had an average concentration of PT, aPTT, fibrinogen, d‐dimer, and platelets of 13.2 ± 0.9 s, 28.9 ± 4.3 s, 679.4 ± 185.1 mg/dL, 1.9 ± 3.1 µg/mL, and 272.8 ± 88.9 cel/10 mm,(3) respectively. We found no differences in the concentration of each marker according to severity (p < 0.05). Patients with severe COVID‐19 had altered the aPTT, fibrinogen, d‐dimer, and PT in 31 (57.4%), 48 (88.9%), 37 (68.5%), and 15 (27.8%) cases, respectively. CONCLUSIONS: Our results showed that although there is an alteration in coagulation markers, mainly fibrinogen and d‐fiber, there are no differences in concentration according to the severity of COVID‐19.